|
M42’s HealthPlus Fertility
and Cleveland Clinic Abu
Dhabi perform ovarian tissue
cryopreservation procedure
(Abu Dhabi, UAE)
-
HealthPlus Fertility, a
renowned leader in fertility
care, and Cleveland Clinic
Abu Dhabi, both part of the
M42 group, has performed an
ovarian tissue
cryopreservation (OTC)
procedure on a single
32-year-old Emirati patient
with Hodgkin lymphoma, a
type of cancer that affects
the lymphatic system. The
procedure was carried out at
Cleveland Clinic Abu Dhabi,
where the patient is
receiving her cancer
treatment, and under the
supervision of HealthPlus
Fertility’s team of experts.
OTC is a pioneering
technique that offers hope
to women undergoing cancer
therapy by preserving their
fertility potential. The
procedure, which was brought
to the region by HealthPlus
Fertility, involves the
careful removal and
preservation of ovarian
tissue, which can later be
re-implanted to restore
fertility once cancer
treatment is completed.
Dr. Monika Chawla,
Medical Director at
HealthPlus Fertility, said:
“We are thrilled to have
achieved this milestone, in
collaboration with Cleveland
Clinic Abu Dhabi. This marks
a significant step forward
in our mission to provide
comprehensive fertility
preservation solutions to
our patients. The teamwork
displayed by both teams was
truly remarkable. It was a
proud moment for all of us
to witness their dedication
and expertise in ensuring
the successful,
life-changing treatment of
the patient’s ovarian tissue
preservation.”
The
procedure’s success was
enhanced by seamless
teamwork between the
medical, surgical, and
embryology teams at
HealthPlus Fertility and
Cleveland Clinic Abu Dhabi.
Dr. Malini Sharma, Staff
Physician, Gynecology,
Surgical Subspecialties
Institute at Cleveland
Clinic Abu Dhabi, said: “We
are proud to be part of this
multidisciplinary and
collaborative effort between
our oncology team, surgical
team, and HealthPlus
Fertility. This pioneering
ovarian tissue
cryopreservation marks a
significant leap forward in
patient care, offering women
undergoing cancer treatments
new hope by providing the
opportunity to preserve
their fertility and plan for
a family in the future.”
Dr. Wael Ismail Madkour,
Obstetrics & Gynecology,
Fertility & Reproductive
Endocrinology (IVF)
Consultant at HealthPlus
Fertility Center said:
“Infertility following
cancer treatments is
considered a major quality
of life issue. Ovarian
tissue cryopreservation and
transplantation are
important options for
fertility preservation in
adult cancer patients who
need immediate chemotherapy.
Ovarian tissue freezing is
the only option for
preserving the fertility of
prepubertal patients with
cancer. This procedure can
make motherhood possible for
cancer survivors.”
During the surgery, the
surgeon removes a part of or
one of the ovaries. Once
extracted, the tissue is cut
into thin strips, soaked in
a preservative solution, and
then transported to the
laboratory for freezing.
The procedure itself
uses ultra-low temperature
‘cryogenic’ freezers to
preserve the ovarian tissue
safely. Once the patient is
completely cured and
planning to start a family,
the frozen ovarian tissue
can be transplanted back
into her pelvis, allowing
normal ovarian function and
egg production to resume,
and for younger patients,
the chance of pregnancy —
either through spontaneous
conception or via IVF after
the transplantation of
ovarian tissue — is higher
than 50 percent.
OTC
represents a vital option
for patients diagnosed with
cancer who wish to protect
their fertility. HealthPlus
Fertility remains committed
to advancing reproductive
medicine and providing
compassionate care to
patients navigating
fertility challenges.
PRINT
THIS ARTICLE
|
